Skip to main
SNTI
SNTI logo

SNTI Stock Forecast & Price Target

SNTI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Senti Biosciences Inc. shows a positive outlook driven by encouraging initial results from its SENTI-202 therapy, which outperformed current therapies with <33% complete response rates, indicating strong potential for future clinical success. The company is also focusing on enhancing its operational efficiency by investing in in-house GMP manufacturing capabilities, which could reduce costs and improve production timelines for its innovative therapies. The anticipated results from ongoing clinical trials, particularly those expected in 4Q25, suggest the possibility of significant upside potential if patient outcomes continue to surpass benchmarks while maintaining durable responses.

Bears say

The analysis highlights a potential negative outlook for Senti Biosciences Inc., primarily due to the risk-adjusted projections and price targets that may face downward revisions. The recurring emphasis on the possibility of adjustments indicates concerns regarding the stability and performance of the company’s financial metrics. Consequently, the likelihood of adverse modifications to financial forecasts further underlines the inherent financial risks associated with Senti Biosciences's current and future operations in the highly competitive biotechnology sector.

SNTI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Senti Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Senti Biosciences Inc (SNTI) Forecast

Analysts have given SNTI a Strong Buy based on their latest research and market trends.

According to 3 analysts, SNTI has a Strong Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Senti Biosciences Inc (SNTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.